Ezabenlimab

• CAT Number: I042109
• CAS Number: 2249882-54-8
• Purity: ≥95%

Ezabenlimab（Cat No.:I042109）is an investigational monoclonal antibody that targets the immune checkpoint protein TIM-3 (T-cell immunoglobulin and mucin domain 3). TIM-3 plays a role in regulating immune responses, often leading to immune suppression in the tumor microenvironment. By inhibiting TIM-3, ezabenlimab aims to enhance T-cell activity and promote the immune system’s ability to fight cancer. It is being studied in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma. The goal is to assess its safety and effectiveness, either as a monotherapy or in combination with other immunotherapies.